

Protein Biomarker Discovery in Organ Transplantation

A Proteomics Approach

Tara Sigdel, PhD

9/26/2011

For personal use only.
Please do not reuse or reproduce
without the author's permission.


Organ Transplantation

- Optimal Choice for end stage organ failure
- Significant number of transplant occur every year

Total transplantation in the US January - June 2011 = 13, 969

(source: <http://optn.transplant.hrsa.gov>)

- Causes of organ dysfunction after transplantation:
 - Donor related
 - Ischemia reperfusion injury
 - Recipient's Immune response
 - Drug toxicity
- Improvements in organ procurement & Immunosuppressive drugs have contributed to short term outcome
- Long-term outcome is still not very satisfactory and needs to be improved




http://www.mode.org.in/organ_transplantation.html

Biomarkers in Transplantation

Biomarker: Substance (molecules such as gene, proteins, metabolites etc) that can be measured to determine the biological, pathological, pharmacological state

Current monitoring relies on dated technologies

- Serum creatinine level
- Histopathology of biopsy samples



N Engl J Med. 2003 Jul 10;349(2):125-38.

Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling.

Sarwal M, Chua MS, Kambham N, Hsieh SC, Satterwhite T, Masek M, Salvatierra O Jr.

Gene Expression & Protein Biomarkers


OPEN  ACCESS Freely available online

PLOS COMPUTATIONAL BIOLOGY

Differentially Expressed RNA from Public Microarray Data Identifies Serum Protein Biomarkers for Cross-Organ Transplant Rejection and Other Conditions

Rong Chen^{1,2}, Tara K. Sigdel^{1,2}, Li Li^{1,2}, Neeraja Kambham³, Joel T. Dudley^{1,2}, Szu-chuan Hsieh^{1,2}, R. Bryan Klassen^{1,2}, Amery Chen^{1,2}, Tuyen Caohuu⁴, Alexander A. Morgan^{1,2}, Hannah A. Valentine⁴, Kiran K. Khush⁴, Minnie M. Sarwal^{1,2*}, Atul J. Butte^{1,2*}


1 Department of Pediatrics, Stanford University School of Medicine, Stanford, California, United States of America, **2** Lucile Packard Children's Hospital, Palo Alto, California, United States of America, **3** Department of Pathology, Stanford University School of Medicine, Stanford, California, United States of America, **4** Division of Cardiovascular Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, California, United States of America



Hypothesis

There is a signature of proteins present in the blood and urine which could serve as non-invasive biomarkers for organ transplant injury

The Goal



Urinary Protein Biomarkers Urine Proteomics



NIH-PA Author Manuscript

NIH Public Access
Author Manuscript

Published in final edited form as:
Proteomics Clin Appl. Author manuscript; available in PMC 2010 June 10.
doi:10.1002/pcra.200900124.

**Shotgun Proteomics Identifies Proteins Specific for Acute Renal
Transplant Rejection**

Tara K. Sigdel¹, Wenzhong Xiao², Amit Kaushal², David G. Camp II³, Richard D. Smith³, and Minnie M. Sarwal¹
¹ Department of Pediatrics, 300 Pasteur Dr, S378 Grant Bldg, Stanford University School of Medicine, Stanford, CA 94301
² Department of Biochemistry
³ Battelle, Pacific Northwest


BASIC RESEARCH

**Integrative Urinary Peptidomics in Renal
Transplantation Identifies Biomarkers for Acute
Rejection**

Xuefeng B. Ling,* Tara K. Sigdel,[†] Kenneth Lau,* Lihua Ying,[†] Irwin Lau,* James Schilling,*
and Minnie M. Sarwal[†]
Divisions of *Biotechnology Core and [†]Nephrology and Department of Pediatrics, Stanford University School of
Medicine, Stanford University, Stanford, California

Optimization of Proteomics Protocol

Sigdel et al. Clin Transplant. 2008 (5):617-23



Urine Protein Biomarkers for Kidney Transplantation Rejection (Study Subjects)

Patient demographic information

Patient information on 60 renal transplant patients (30 AR, 30 STA).

	Acute Rejection (AR) (n=30)	Stable Graft Function (STA) (n=30)	P value
Mean Age	12±5	14±5	0.21
Age Range	3–19	6–21	
Immunosuppression, %SF [#]	66%	50%	0.19
Race *	63%,13%,0%,17%,7%	59%,7%,10%,17%,7%	0.45
Donor, % living donor	40%	53%	0.44
Mean GFR (mL/min/1.73m ²)	87.45±38.46	124±29.86	0.0001


[#] SF: Steroid-free immunosuppression treatment, consisting of daclizumab induction + mycophenolate mofetil + tacrolimus

* Race: 1=Caucasian; 2= Hispanic; 3=Asian; 4=African American; 5=Other

Shotgun Proteomics Analysis of Urine Identifies AR Specific Urine Markers

Sigdel et al *Proteomics Clin Appl.* 2010 Jan 1;4(1):32-47

High throughput proteomics using shotgun proteomics identified a total of 1446 urinary proteins which included a number of AR specific proteins.



We have identified alterations in a number of specific urinary proteins in AR, primarily relating to MHC antigens, the complement cascade and extra-cellular matrix proteins.

Selected candidates were verified by ELISA in an independent urine sample set

Identification of More Proteins in Urine

Sigdel et al *Proteomics Clin Appl.* 2010 Jan 1;4(1):32-47

This work
(1340)

Adachi et al
(1543)

Gonzalez et al
(1160)



Acute Rejection Specific Proteins


Sigdel et al *Proteomics Clin Appl.* 2010 Jan 1;4(1):32-47

Table 4A: List of proteins identified only in AR urine

S. No.	IPI ID	Gene Symbol	Protein Name
1	IPI00103082.7	<i>HLA-DBP</i>	HLA class II histocompatibility antigen, DP(W4) beta chain
2	IPI00005180.2	<i>IgHM</i>	HLA class II histocompatibility antigen, DRB1-8 beta chain
3	IPI00021727.1	<i>C4BPA</i>	C4b-binding protein alpha chain
4	IPI00641889.1	<i>KIAA1522</i>	25 kDa protein
5	IPI00746396.1		302 kDa protein
6	IPI00760688.2	<i>HLA-DR</i>	MHC class II antigen (Fragment)
7	IPI00027255.1	<i>MYL6B</i>	Myosin light chain 1, slow-twitch muscle A isoform
8	IPI00783351.1	<i>SUMF2</i>	sulfatase modifying factor 2 isoform d
9	IPI00743218.1	<i>HLA-DQBI</i>	HLA class II histocompatibility antigen, DQ(3) beta chain

Transplantation and AR Specific Proteins

Sigdel et al *Proteomics Clin Appl.* 2010 Jan 1;4(1):32-47





Verification of Urine Protein Markers

UMOD, SERPINF1 and CD44 (ELISA Assay)

Sigdel et al *Proteomics Clin Appl.* 2010 Jan 1;4(1):32-47

We validated observation made in discovery step by ELISA assay performed on independent set of samples.





Shotgun proteomics approach for analyzing urinary proteome in normal and disease states is a robust and sensitive method for detection of urinary proteins for serial, non-invasive clinical monitoring for graft rejection after kidney transplantation.

Integrative Urinary Peptidomics in Renal Transplantation Identifies Novel Biomarkers for Acute Rejection

Ling and Sigdel et al JASN 2010 Apr;21(4):646-53

Peptidomics approach for biomarker discovery (70 urine samples) (50 renal transplant and 20 controls)






We identified a panel of 40 peptides that discriminates AR from non-AR, ROC AUC>0.96

Verification of Urine Peptide Markers

Ling and Sigdel et al JASN 2010 Apr;21(4):646-53

SRM verification of two UMOD peptide biomarkers



Discovery of Disease Specific Proteolytic Activity

Collagens



1.	COL1A1	1235.56	APGDRGE P GGPPGP
2.	COL1A1	1251.55	APGDRGE P GGPPGP]
3.	COL1A1	1322.57	APGDRGE P GGPPGA
4.	COL1A1	1316.59	DAGPVGFP G GGPPPG
5.	COL1A1	1409.66	GPPGPPGPPGPPGPPS]
6.	COL1A1	2048.92	NGDDGEAGKPGRPGERGFPGP
7.	COL1A1	2064.91	NGDDGEAGKPGRPGERGFPGP]
8.	COL1A1	2192.97	NGDDGEAGKPGRPGERGFPGQ
9.	COL1A1	2362.12	GKNGDDGEAGKPGRPGERGFPGQ]
10.	COL1A1	2378.10	GKNGDDGEAGKPGRPGERGFPGQ]
11.	COL1A1	2645.24	GPPGKNGDDGEAGKPGRPGERGFPGQ]
12.	COL1A1	1709.79	PPGEAGKPGEGVPGDILG
13.	COL1A1	2031.95	PPGEAGKPGEQGVPGDILGAPGP]
14.	COL1A1	2221.97	ADQPGAKGE P GDAGAKGDAGPPGP
15.	COL1A1	2205.99	ADQPGAKGE P GDAGAKGDAGPPGP]
16.	COL1A1	2277.01	ADQPGAKGE P GDAGAKGDAGPPGP]
17.	COL1A1	2293.01	ADQPGAKGE P GDAGAKGDAGPPGP]
18.	COL1A1	2617.15	GPPGADQPGAKGE P GDAGAKGDAGPPGP]
19.	COL1A1	2086.93	EAGSPGRDGSPGAKGDRGETGPA]
20.	COL1A1	2157.96	AEGSPGRDGSPGAKGDRGETGPA]
21.	COL1A1	3014.41	ESGREGAPGAEGSPGRDGSPGAKGDRGETGPA]
22.	COL1A1	1266.58	SPPGPDGKTPGP GPA]
23.	COL1A1	2129.99	DGKTPPPGPAQDGDRPGPPGPP]
24.	COL1A1	2017.93	GRPGEVGP P PPGPPAGEKGSPG]
25.	COL1A2	2081.94	DGPPGRDGQPGHKGERGYPG]
26.	COL1A2	2195.99	NDGPPGRDGQPGHKGERGYPG]
27.	COL2A1	1861.85	SNGNPGPFPGP SGKDGPK]
28.	COL3A1	1738.76	NDGAPGKNGERGGPGGP]
29.	COL3A1	2008.93	DGESGRPGRPGERGLPGLP]
30.	COL3A1	2079.92	DAGAPGAFGGKDAGAPGERGPPG]
31.	COL3A1	2565.18	GA P QGN P GGKGERGA P CEKGE G PPG]
32.	COL3A1	2743.24	KNGETGPQGP P GTGP G DKGDTGP G PPGP]
33.	COL4A1	1424.66	PQ Q GN P GA Q GLPGP]
34.	COL4A2	1126.51	GLPGLP G KGFA]
35.	COL4A3	1161.52	GEPPGPPGP G NLG]
36.	COL4A4	1218.55	GLP G PPGP G KPRG]
37.	COL4A5	1144.52	GP G PPGP G PLGP]
38.	COL4A5	1269.53	PGLDGMKGD G PLP]
39.	COL4A5	1733.76	GIKGEKGN P QGPGLPGLP]
40.	COL4A6	1158.52	GLP G PPGP G PPPS]
41.	COL5A1	1748.82	KGPQGKPGLAGMPGAN G PP]
42.	COL7A1	1690.80	PGLPGQVGETGKPGAPGR]
43.	COL9A1	1732.84	KRDPDSATGLPGR G PPG]
44.	COL11A1	1441.64	GPPGPPGLP G PPGPKG]
45.	COL11A1	1828.84	DGP G PPGPGERGPQGPQGPV]
46.	COL17A1	1368.62	LPGP G PPGSFLSN]
47.	COL18A1	1142.51	GPPGPPGP G PPPS]


Uromodulin



1.	UMOD	982.59	VNLGPITR
2.	UMOD	1047.48	SGSVIDQSRV
3.	UMOD	1211.66	DQSRVNLGPITR
4.	UMOD	1225.69	SRVNLGPITR
5.	UMOD	1324.76	IDQSRVNLGPITR
6.	UMOD	1423.83	VIDQSRVNLGPITR
7.	UMOD	1468.82	DQSRVNLGPITR
8.	UMOD	1510.87	SVIDQSRVNLGPITR
9.	UMOD	1567.91	GSVIDQSRVNLGPITR
10.	UMOD	1581.91	IDQSRVNLGPITR
11.	UMOD	1654.91	SGSVIDQSRVNLGPITR
12.	UMOD	1680.98	VIDQSRVNLGPITR
13.	UMOD	1755.96	SGSVIDQSRVNLGPIT
14.	UMOD	1768.01	SVIDQSRVNLGPITR
15.	UMOD	1912.07	SGSVIDQSRVNLGPITR
16.	UMOD	2040.16	SGSVIDQSRVNLGPITR

Decreased Fragments of COL and UMOD in AR


Ling and Sigdel et al J Am Soc Nephrol. 2010



Transcription-Translation-Proteolysis

Is there an altered gene expression for the precursor gene of biomarker peptides in AR?

Ling and Sigdel et al J Am Soc Nephrol. 2010




Biopsy arrays chosen for study on overlapping **urine peptidomic** samples for 20 AR, 20 STA and 10 HC.

A Panel of genes as biomarkers specific for AR (Q-PCR validation)


Ling and Sigdel et al J Am Soc Nephrol. 2010

Kidney gene expression analysis:


1. Upregulation of COL1A2, COL3A1, MMP7, SERPING1, and TIMP1
2. Downregulation of UMOD



Q-PCR validation




A New Understanding



Protein Biomarkers in the Blood

Serum Proteomics

Serum Protein Biomarkers Study Design



Patient Demography

Discovery (n=60) (50 transplantation 10 healthy normal)

Phenotype	AR	STA	CAN	CNIT	BKV
Number of Patients	10	10	10	10	10
Steroid-free/Steroid-based	5/5	4/6	3/7	8/2	6/4
Recipient Gender (M/F)	6/4	7/3	6/4	8/2	7/3
Recipient Age*	12 ± 5 (14; 10-19)	16 ± 3 (16; 10-19)	12 ± 6 (9; 8-18)	11 ± 6 (11; 3-17)	13.5 ± 7 (18; 1-20)
Living/Deceased	3/7	5/5	1/2	3/7	6/4
Donor Gender (M/F)	5/5	6/4	4/6	6/4	7/3
Donor Age*	28 ± 8 (29; 17-37)	28 ± 10 (27; 14-47)	24 ± 8 (25; 16-31)	28 ± 10 (28; 17-37)	29 ± 9 (30; 16-47)

Verification (n=71) (71 transplantation sera)

Number of Patients	16	15	17	10	13
Steroid-free/Steroid-based	9/7	9/6	8/9	5/5	9/4
Recipient Gender	12/4	10/5	6/11	5/5	8/5
Recipient Age*	12 ± 5 (14; 3-19)	13 ± 7 (16; 1-20)	8 ± 6 (7; 1-17)	13 ± 5 (15; 4-20)	11 ± 8 (15; 1-19)
Living/Deceased	13/3	2/13	10/7	6/4	11/2
Donor Gender	8/8	8/7	11/6	7/3	10/3
Donor Age*	24 ± 5 (14; 5-38)	23 ± 6 (23; 14-36)	30 ± 10 (28; 14-44)	35 ± 5 (37; 29-44)	27 ± 16 (29; 1-49)

Heart transplantation sera (n=29)

Lung transplantation sera (n=27)

Work Flow



Sera Retrieval



Immunodepletion

To deplete 20 highly abundant proteins from serum



Protein Assay



Trypsin Digestion




MS MS/MS Analysis



Data Analysis

There is slightly increased protein presence in AR Overall



Antibody Biomarkers in the Blood

High-density Protein Arrays “Antibiomics”


Identifying compartment-specific non-HLA targets
after renal transplantation by integrating
transcriptome and “antibodyome” measures

Li Li^a, Persis Wadia^b, Rong Chen^c, Neeraja Kambham^d, Maarten Naesens^a, Tara K. Sigdel^a, David B. Miklos^b,
Minnie M. Sarwal^{a,1}, and Atul J. Butte^{a,c,1}

^aDepartment of Pediatrics, Blood and Marrow Transplantation Division, Departments of ^bMedicine and ^dPathology, and ^cCenter for Biomedical Informatics Research, Stanford University, 300 Pasteur Drive, Stanford, CA 94304



Immune Response Markers for Chronic Allograft Injury



Conclusion

- There is a dire need of more sensitive and specific biomarkers
- Carefully designed proteomics studies on appropriate samples could provide potential biomarkers for diagnosis and monitoring of transplant dysfunction
- Our effort in this field has yielded a number of potential biomarker proteins and peptides that could provide more specific and sensitive biomarkers that can be used in clinical setting

Acknowledgements

- Minnie Sarwal, Dept of Pediatrics
- David Camp and Wei-Jun Qian (Pacific Northwest National Lab, Richland, WA)
- Bruce Ling, Ken Lou, and Jim Schlling(Dept of Pediatrics, Stanford Univ)
- Van Dinh ,Tim Tran, Bryan Klassen, Many Mohindra, and other Sarwal Lab members
- SUMS , Stanford Univ
- NIH for funding